| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Dipyridamole-d20 targets the same enzymes as its non-deuterated counterpart, primarily phosphodiesterases (PDEs), with a particular affinity for PDE5A. Additionally, dipyridamole inhibits the cellular uptake of adenosine, thereby potentiating its vasodilatory and antiplatelet effects. The deuterated form is used as an analytical tracer to study these interactions.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As an internal standard, Dipyridamole-d20 is not typically evaluated for its own in vitro activity. However, the parent compound dipyridamole is a potent vasodilator that inhibits platelet aggregation and exhibits antiviral and anti-inflammatory properties. The deuterated form is assumed to possess identical physicochemical properties, allowing it to accurately mirror the behavior of the unlabeled drug in biological assays. |
| ln Vivo |
The in vivo activity of Dipyridamole-d20 is not separately characterized, as it is used as a tracer. The parent compound dipyridamole is clinically used as an antiplatelet agent and for myocardial perfusion imaging. The deuterated form is administered in pharmacokinetic studies to trace the distribution and metabolism of the parent drug in living organisms.
|
| Enzyme Assay |
In vitro assays for Dipyridamole-d20 typically involve its use as an internal standard in LC-MS or GC-MS methods. The compound is spiked into biological samples (e.g., plasma, tissue homogenates) prior to extraction. Its deuterium atoms provide a distinct mass shift, allowing for precise correction of matrix effects, ionization efficiency, and recovery during quantitative analysis of dipyridamole.
|
| Cell Assay |
For in vitro cell assays, Dipyridamole-d20 is not used as a direct treatment. Instead, it is used as an analytical tool. Cells are treated with unlabeled dipyridamole, and the deuterated compound is added to cell lysates or supernatants as an internal standard for the accurate quantification of drug uptake and metabolism by LC-MS.
|
| Animal Protocol |
For in vivo animal studies, Dipyridamole-d20 is administered to rodents alongside or instead of the unlabeled drug. Blood and tissue samples are collected at various time points. The compound is extracted and analyzed by LC-MS, using the deuterium label to distinguish it from endogenous compounds and to accurately measure the pharmacokinetic parameters of dipyridamole.
|
| ADME/Pharmacokinetics |
Dipyridamole-d20 has a molecular weight of 524.75 and a molecular formula of C₂₄H₂₀D₂₀N₈O₄. It is typically stored as a powder at -20°C. The compound is soluble in DMSO. Its deuterium labeling provides a mass shift of +20 Da, which is crucial for its function as an internal standard in mass spectrometry. As a labeled compound, its pharmacokinetic properties are assumed to be identical to those of unlabeled dipyridamole.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are available for Dipyridamole-d20. As an isotopically labeled compound, its toxicity profile is expected to be comparable to that of the parent drug dipyridamole at equivalent doses. Dipyridamole is generally well-tolerated, with common side effects including headache, dizziness, and gastrointestinal disturbances. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
Dipyridamole-d20 (CAS# 1189983-52-5) is a stable isotope-labeled compound used exclusively as a research tool. It has not been investigated in clinical trials nor approved as a therapeutic drug. Its primary application is in pharmaceutical research and development for the quantitative analysis of dipyridamole in complex biological matrices. It is a valuable reagent for bioanalytical method development and validation.
|
| Molecular Formula |
C24H40N8O4
|
|---|---|
| Molecular Weight |
524.748838424683
|
| Exact Mass |
524.442
|
| CAS # |
1189983-52-5
|
| Related CAS # |
Dipyridamole;58-32-2
|
| PubChem CID |
45039101
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
0.7
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
36
|
| Complexity |
561
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCCN(CCO)C1=NC2C(C(=N1)N1C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C1([2H])[2H])=NC(N(CCO)CCO)=NC=2N1C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C1([2H])[2H]
|
| InChi Key |
IZEKFCXSFNUWAM-KHKAULECSA-N
|
| InChi Code |
InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2/i1D2,2D2,3D2,4D2,5D2,6D2,7D2,8D2,9D2,10D2
|
| Chemical Name |
2-[[2-[bis(2-hydroxyethyl)amino]-4,8-bis(2,2,3,3,4,4,5,5,6,6-decadeuteriopiperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9057 mL | 9.5283 mL | 19.0567 mL | |
| 5 mM | 0.3811 mL | 1.9057 mL | 3.8113 mL | |
| 10 mM | 0.1906 mL | 0.9528 mL | 1.9057 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
